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Abstract
Damage to endothelial cells contributes to acute kidney injury (AKI) by leading to impaired perfusion.
Endothelial colony-forming cells (ECFC) are endothelial precursor cells with high proliferative capacity,
pro-angiogenic activity, and in vivo vessel forming potential. We hypothesized that ECFC may ameliorate
the degree of AKI and/or promote repair of the renal vasculature following ischemia-reperfusion (I/R). Rat
pulmonary microvascular endothelial cells (PMVEC) with high proliferative potential were compared with
pulmonary artery endothelial cells (PAEC) with low proliferative potential in rats subjected to renal I/R.
PMVEC administration reduced renal injury and hastened recovery as indicated by serum creatinine and
tubular injury scores, while PAEC did not. Vehicle-treated control animals showed consistent reductions in
renal medullary blood flow (MBF) within 2 h of reperfusion, while PMVEC protected against loss in MBF
as measured by laser Doppler. Interestingly, PMVEC mediated protection occurred in the absence of
homing to the kidney. Conditioned medium (CM) from human cultured cord blood ECFC also conveyed
beneficial effects against I/R injury and loss of MBF. Moreover, ECFC-CM significantly reduced the
expression of ICAM-1 and decreased the number of differentiated lymphocytes typically recruited into the
kidney following renal ischemia. Taken together, these data suggest that ECFC secrete factors that preserve
renal function post ischemia, in part, by preserving microvascular function.
Keywords: angiogenesis, endothelial progenitor, hemodynamics, regeneration
උൾඇൺඅ ංඌർඁൾආංൺ-උൾඉൾඋൿඎඌංඈඇ (I/R) impairs vascular function by reducing renal blood flow and
glomerular filtration while promoting parenchymal cell damage and sustained injury. It has become
increasingly clear that the renal endothelium is a critically important target in the injury process as factors
geared toward preserving endothelial function lessen the severity of I/R-induced renal damage (6). This
endothelial damage may compromise renal blood flow by imparting changes in vascular tone and/or
increasing inflammatory responses. In recent years, there has been a substantial number of reports
suggesting that proangiogenic cell-based therapies provide protective effects against renal I/R (14–16, 36,
47, 50, 52, 54–56, 60). For example, mesenchymal stem cells (MSCs) from bone marrow and adipose
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Animals.
Cells.
tissue produce paracrine vasculotrophic factors thought to be important in the protection against renal I/R
(42, 46, 50, 52, 54–56). Similarly, bone marrow-derived pro-angiogenic cells can significantly attenuate the
degree of injury following I/R (29, 39). These cells provide beneficial effects against the development of
injury, but do not incorporate into regenerating kidney to influence repair processes (14, 29). Other
investigations have sought to directly replace endothelial function via transplantation of human umbilical
vein endothelial cells (HUVEC) to athymic rats, which preserved postischemic microvascular flow in an
endothelial nitric oxide synthase-dependent fashion and protected against subsequent renal damage (13).
In addition to acute endothelial dysfunction, there is a significant reduction in peritubular capillary density
following acute kidney injury (AKI) (7). This reduction in peritubular capillary density is characterized by
low endothelial cell proliferation and propensity to undergo endothelial-to-mesenchymal transition (5).
Since the endogenous renal vasculature demonstrates little reparative capacity (5), strategies directed
toward vascular protection or revascularization may be considered an important goal in maintaining short-
term or long-term function in response to renal injury.
Yoder and colleagues have described non-hematopoietic endothelial progenitor cells referred to as
endothelial colony-forming cells (ECFC), which can be derived from peripheral blood or tissues (2). ECFC
with high proliferative potential (HPP) in single-cell colony-forming assays form perfused vessels in vivo
and are considered true endothelial progenitor cells (64). It has been shown that human cord blood as well
as HUVEC represent a rich source of human HPP-ECFC (31, 63, 69). However, the proliferative potential
of ECFC varies depending on species, age, and tissue source. For example, Alvarez et al. (3) showed that
rat pulmonary microvascular endothelial cells (PMVEC) have a substantially greater proportion of HPP-
ECFC compared with rat pulmonary artery-derived cells (PAEC). Since HPP-ECFC are bone fide
vasculoreparative cells, we hypothesized that supplementation with HPP-ECFC may influence the course
of renal injury, and potentially engraft into the damaged kidney. To that end, we sought to investigate the
effect of endothelial transplantation based upon the proliferative potential of ECFC following renal I/R.
METHODS
Male Sprague-Dawley rats (initial weight ~250 g) were utilized in all studies. Rats were given
free access to standard rat chow and water throughout our studies. Experiments were conducted in
accordance with National Institutes of Health guidelines and were approved by the Indiana University
School of Medicine Institutional Animal Care and Use Committee.
Rat pulmonary microvascular endothelial cells (PMVEC) and rat pulmonary artery cells (PAEC)
were isolated and expanded as described previously (3). These primary cultures were derived from Sprague
Dawley rats and utilized between passages 5 and 7. The endothelial nature of PMVEC and PAEC was
previously characterized by Alvarez et al. (3) and cells were validated according to their expression of
CD31, KDR, and vWF, but were negative for CD45 and CD133. PMVEC have a significantly faster
proliferation rate and a greater percentage of high proliferative potential HPP-ECFC than PAEC (3).
PMVEC and PAEC were maintained in EGM-2 supplemented with 10% FBS (Hyclone) and grown on T75
flasks. On the day of transplant studies, cells were harvested by trypsin digestion, washed with PBS. In
some studies, the cells were labeled with CMTPX (i.e., Cell tracker red, Invitrogen), according to the
manufacturer’s instructions. The cells were then washed and resuspended in serum-free culture medium
and maintained on ice until the time of transplant.
Human ECFC were derived from human cord blood according the protocol described previously by Yoder
et al. (64). Human ECFC were maintained in T-225 flasks in EGM2 (Invitrogen) with 10% FBS. Fifty
milliliters of conditioned serum-free medium was derived from 50 to 75% confluent human ECFC,
corresponding to ~8–12 million cells following 2 days of incubation and concentrated by centrifugation
using Centricon filters (3000 M.W. cutoff) to achieve an enrichment of ~10-fold. Therefore, 1 ml of CM
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Surgeries.
Measurement of renal function.
Evaluation of KIM-1 or ICAM-1 mRNA expression in the injured kidney.
Evaluation of renal hemodynamic response to I/R injury.
Evaluation of cell homing.
results from the contribution of ~1.6–2.4 million cells.
Acute kidney injury was induced by bilateral ischemia reperfusion injury to the kidneys by
clamping both renal pedicles for 40 min using a surgical approach that has been described previously under
anesthesia induced with ketamine (100 mg/kg) and pentobarbital (25–50 mg/kg) (40) or ketamine (100
mg/kg) and xylazine (5 mg/kg). The first cocktail was used in the initial series of experiments in which rat
ECFC were tested; while the second anesthetic cocktail was used in studies of human ECFC derived
conditioned media. The reason for the change was due to limited availability of pentobarbital which
occurred between the times of the two studies. These two anesthetic regimens yielded consistent levels of
renal injury.
For endothelial cell administration, we utilized an approach similar to that described by Brodsky et al., for
the administration of HUVEC (13). The left carotid artery was cannulated with a PE-50 tubing filled with
heparinized sterile saline, inserted toward the heart, while the artery distal to the insertion site was ligated
with a silk-suture to prevent backleak. This catheter was utilized for the administration of cells (5 × 10
PMVEC or PAEC in 0.5 ml of vehicle) in a retrograde fashion immediately following the release of the
clamps. The catheter was then slowly withdrawn and the carotid artery was immediately ligated proximal
to the insertion site to prevent bleeding. In studies using ECFC-conditioned media, a volume of 0.5 ml of
10× concentrated conditioned media or “mock”-conditioned media from human ECFC was administered to
the suprarenal aorta at the time of reperfusion using a 31-gauge needle.
At the indicated times, blood was obtained from rats under light
isoflurane anesthesia via tail vein incisions. Blood was collected in 1.5-ml heparinized Eppendorf tubes,
centrifuged at 3,000 g for 10 min. Serum creatinine was measured using a Point Scientific QT 180
Analyzer and creatinine reagent kit (Point Scientific, Canton, MI) according to the manufacturer’s
specifications (57).
Whole kidney mRNA was
extracted from fresh-frozen tissue using a Direct-zol RNA extraction kit according to the manufacturer's
instructions (Zymo, Irvine, CA). Kidney injury molecule-1 (KIM-1) mRNA expression was evaluated
using predesigned Taqman primers (Life Technologies, Carlsbad, CA) with the 2 C  analysis method
(30).
Rats were anesthetized with ketamine HCl (60
mg/kg), followed by Inactin (50–100 mg/kg) ip and placed on a heated surgical board to maintain body
temperature at 37°C. The femoral vein was cannulated for intravenous infusion of 2% bovine serum
albumin in 0.9% NaCl at a rate of 2 ml·h ·100 g body wt . This catheter was also used for infusion of
conditioned medium.
A midline abdominal incision was made, and a flow probe was placed around the renal artery for
measurement of renal blood flow (RBF) via an ultrasonic Doppler flowmeter (model T206; Transonic
Systems, Ithaca, NY). The left kidney was placed in a holder and an optical probe for laser Doppler
flowmetry (Transonic) was implanted to a depth of 5.0 mm beneath the surface for measurements of renal
outer medullary blood flow (MBF). Data were recorded using Biopac (Goleta, CA) data-acquisition
software.
Following 30 min of equilibration, RBF and MBF values were measured for 30 min in 10-min time bins,
with the final 10 min defined as baseline. Parameters were measured during ischemia and an additional 120
min of reperfusion. Values were normalized to each baseline value, and data are expressed as the average of
these normalized values.
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Evaluation of infiltrating leukocytes.
Renal histology and immunohistochemistry.
Immunofluorescent analysis of ICAM-1.
Statistical analysis.
described above. Pilot studies indicated that tissue fixation impaired our detection of labeled cells.
Therefore, cell fluorescence was examined in freshly harvested unfixed tissues. Kidneys, spleens, or lungs
were removed from deeply anesthetized rats and immersed in ice-cold HEPES-Tyrode buffer (132 mM
NaCl, 4 mM KCl, 1 mM CaCl , 0.5 mM MgCl , 10 mM HEPES, and 5 mM glucose, pH 7.4) that had been
bubbled with 100% O . Tissue slices were prepared using a hand microtome (Stadie Riggs Tissue Slicer)
and stored in cold buffer and imaged within 1 h of tissue harvest. Images were obtained using a Zeiss LSM
NLO confocal microscope equipped with AR and HeNe lasers and a ×40 water immersion lens, and a
signal was obtained by 545 nm and detection at 565–615 nm.
Harvested kidneys were minced and digested in TL Liberase (2
µg/ml; Roche). The obtained cell suspension was filtered through a 100-μm filter mesh and washed with
DMEM containing 10% fetal bovine serum (Cell Applications, San Diego, CA). The mononuclear cells
were separated by Percoll (Sigma, St. Louis, MO) and counted by hemocytometer. To evaluate T
lymphocytes, the cells were stained with antibodies against rat CD4 (PE-Cy7: BD Biolgend, San Diego,
CA), CD8a (Alexa 647: BD Biolgend). To evaluate the cytokines secreted by T cells, the cells were stained
for the CD4 surface marker, permeabilized using 0.1% saponin and stained with antibodies against rat
IFN-γ (FITC: BD Biolgend) or IL-17 (FITC: BD Biolgend). Cells were scanned using flow cytometry
(FACSCalibur, BD Biosciences), and scans were analyzed using Flowjo software (Tree Star, Ashland, OR).
The gating strategy used for these analyses was exactly as we have previously described (32). The total
numbers of the different T cell populations in the harvested kidney were calculated using the percentage of
each cell type and the total cell number measured per gram of kidney.
Renal tubular damage was evaluated from formalin-fixed,
paraffin-embedded samples stained using periodic acid-Schiff (PAS). Six random images (3 cortex, 3 outer
medulla) were obtained using a Leica DMLB microscope (Scientific Instruments, Columbus, OH) using a
×20 objective. For each kidney, an average of 60 tubules were scored from images by an observer who was
blinded to the treatments using a 1–4 scoring system described previously (8). Data presented are based on
the average score per tubule corresponding to each animal.
Methanol-fixed 100-μm vibratome sections of kidneys were
subjected to immunofluorescent staining using an ant-ICAM-1 antibody (BD Biosciences, San Jose, CA).
ICAM-1-specific signals were developed using a tyramide-signal amplification kit (Invitrogen, Carlsbad,
CA) as described previously (9). Confocal images were obtained using an Olympus FV 1000-MPE
microscope using a ×20 objective (Center Valley, PA). Quantification of immunofluorescence was done
with the aid of Fiji ImageJ. Data presented are based on the % total ICAM-1-stained area.
Data are expressed as means ± SE. Differences in means were established by
Student’s t-test or ANOVA as indicated. The 0.05 level of probability was utilized as the minimum criterion
of significance. All statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software, La
Jolla, CA).
RESULTS
The potential that ECFC may alter the course of renal dysfunction and/or repopulate the renal
microvasculature as a function of proliferative potential was addressed by comparing the effect of
administered rat PMVEC, which have a high percentage of HPP-ECFC, or rat PAEC, which have a low
percentage of HPP-ECFC (3). Renal injury measured by increased serum creatinine was most prominent at
2 days of reperfusion. Relative to vehicle-treated control rats, PMVEC-treated rats had a lower peak
creatinine level and a faster recovery of serum creatinine levels (Fig. 1A). In contrast, PAEC administration
did not alter the course of renal injury relative to vehicle-treated rats. Despite evidence of recovery in all
groups, the level of histological damage remained severe in post-ischemic, vehicle-treated animals at day 7
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with evidence of sloughed cells and tubular dilatation in the outer medulla compared with PMVEC-treated
rats (Fig. 1B). To further investigate the protective effect of PMVEC, additional animals were studied at 2
days following reperfusion. Similar to Fig. 1A, PMVEC-treated rats had lower peak serum creatinine levels
(Fig. 1C) and reduced necrotic damage compared with vehicle-treated, postischemic rats (black arrows;
Fig. 1, D and E).
To investigate the potential mechanism of PMVEC-mediated protection, we investigated whether these
cells influenced hemodynamic function in the early postischemic period by measuring total RBF and outer
medullary blood flow (MBF) following reperfusion. Total RBF values rapidly recovered during the
reperfusion phase and were similar to baseline values within 30–40 min. At 2 h of reperfusion, total RBF
was ~90–95% of baseline in both vehicle-treated and PMVEC-treated animals (not significant; Fig. 2A). In
contrast, MBF gradually declined over the course of 2 h following reperfusion in vehicle-treated rats.
However, PMVEC-treated rats had significantly preserved MBF relative to vehicle-treated rats (Fig. 2B).
To determine whether transplanted PMVEC home to the postischemic kidney, cells were labeled with
Celltracker red (CMTPX) just before administration and examined immediately following tissue harvest by
confocal microscopy (Fig. 3A). There was no evidence of fluorescently labeled cells in postischemic
kidneys at either 2 or 48 h following reperfusion (Fig. 3, B and C). In contrast, some fluorescently labeled
cells were readily apparent in the spleen (white arrows, Fig. 3D) and lung (not shown).
The lack of PMVEC homing suggests that soluble factors released from ECFC may provide protection
against impaired renal blood flow following renal I/R. We conducted pilot studies to investigate whether
soluble factors present in conditioned media of PMVEC may mediate protection from I/R injury. In one
pilot study (n = 4), we utilized 5 ml of PMVEC-CM administered intraperitoneally and found that the
increase in serum creatinine measured 24 h following reperfusion was significantly reduced by 44 ± 10%
relative to mock CM-treated post-I/R rats (data not shown). However, to increase the translational
relevance of this research, we sought to utilize CM from human cord blood ECFC, which have very high
proliferative potential (63). In addition, we further modified our approach by concentrating hECFC-CM to
facilitate a reasonable volume for intravascular administration. Relative to vehicle-injected control rats,
hECFC-CM-treated rats manifested a significantly lower peak creatinine level following reperfusion (
Fig. 4A). In addition, the level of histological damage was significantly less severe in ECFC-CM-treated
rats compared with vehicle-treated animals at 2 days post-I/R (Fig. 4, B and C). To further assess renal
injury, we evaluated KIM-1 mRNA expression and demonstrated that the expression of this marker for
tubular injury was significantly reduced compared with vehicle-injected control rats (Fig. 4D).
To determine whether human ECFC-CM administration preserves hemodynamic function postischemia, we
measured total RBF and outer MBF. Similar to studies described in Fig. 2A, total RBF values recovered to
~85% of control during the reperfusion phase and were not different between vehicle- and ECFC-CM-
treated groups (Fig. 5A). In addition, MBF values returned toward control levels in hECFC-CM-treated
animals, but remained significantly suppressed below baseline in vehicle-treated controls (Fig. 5B).
It is has been suggested that endothelial cell dysfunction leads to increased leukocyte adhesion, which may
contribute to the severity of renal damage in the post-ischemic state (5, 35). To determine whether hECFC-
CM suppresses postischemic endothelial leukocyte adhesion, we first measured the mRNA expression of
ICAM-1, an adhesion molecule known to be induced in endothelial cells in the early postischemic period
and demonstrated that its expression was significantly increased within 5 h of reperfusion relative to sham.
(Fig. 6A). Similarly, ICAM-1 protein was not detectable in kidneys of sham-operated rats while it was
prominently induced in peritubular capillaries of postischemic rats as indicated by immunofluorescence (
Fig. 6, B and C). Interestingly, both the mRNA expression of ICAM-1 (Fig. 6A) and the peritubular
capillary protein expression of ICAM-1 (Fig. 6, B and C) were significantly attenuated by infusion of
hECFC-CM.
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To determine whether hECFC-CM reduces postischemic inflammation, total and specific leukocyte
populations were measured by FACS following 2 days of recovery from renal I/R (Fig. 7A). The total
number of leukocytes, as well as the total number of CD4+ and CD8+ cells, were significantly elevated
following renal I/R, but these were not influenced by the hECFC-CM (Fig. 7, B–D). Interestingly,
alterations in specific populations were observed. For example, the total number of cells expressing the
cytokine IL-17 (Fig. 7E) as well as T-helper 17 cells (i.e., CD4+/IL17+) was significantly attenuated in
hECFC-CM-treated rats (Fig. 7F). Moreover, Th-1 cells, defined as CD4+/IFN-γ+, were also significantly
attenuated in hECFC-CM-treated rats (Fig. 7G). These data suggest that reductions in specific anti-
inflammatory cells may contribute to ECFC-mediated protection from I/R induced AKI.
DISCUSSION
A long-term goal of cell-based therapy in the kidney seeks to protect renal perfusion via reducing the extent
of vascular injury and/or promoting of vascular repair. Various cells of hematopoietic origin, often referred
to as endothelial progenitor cells (EPC) or proangiogenic cells, have been identified which may promote
vascular repair (4, 45) while numerous studies have demonstrated that a variety of different cell types can
ameliorate the severity of AKI in preclinical models (14, 15, 36, 52, 54–56, 58, 61, 68).
ECFC are clonally distinct from hematopoietic CFU-ECs, have robust proliferative potential and form
perfused vessels in vivo through a process of de novo vasculogenesis (64). In addition, these cells can be
isolated from the vessel walls of a variety of tissue sources, suggesting that endothelial progenitors reside
within the local vasculature (62). Alvarez et al. (3) demonstrated that PMVEC contain a high percentage of
HPP-ECFC, from which >60% of the populations form colonies of >2,000 cells. In comparison, PAEC, are
less proliferative containing only ~15% HPP-ECFC (3). In addition, we demonstrated that rat kidney
contains little HPP-ECFC activity (10), and therefore PMVECs, rather than kidney-derived cells, were
utilized in this study to evaluate the potential benefit of HPP-ECFC in the setting of AKI. The current study
demonstrates that PMVEC have a powerful protective effect against I/R-induced renal injury, a property
that was not shared by PAEC. These results are consistent with effects reported by Brodsky et al. (13)
demonstrating HUVEC preserved early microvascular dysfunction and mitigated renal injury in athymic
rats following I/R. It has been previously demonstrated that HUVEC contain a high level of HPP-ECFC
(24).
Whether HPP-ECFC within PMVEC are responsible for mediating the protection is not yet clear. The
isolation of HPP-ECFC has not been previously considered feasible based on expression of surface
markers; however, endothelial cells have been shown to possess a side population based on differential
Hoechst 33342 staining, which are enriched in colony-forming potential. These cells were shown to
enhance the regeneration of endothelium in a hind limb ischemia model (37). Whether side population EC
from PMVEC or other vascular beds can specifically contribute to renal protection will represent an
important area of future investigation.
We hypothesized that ECFC, would home to the sites of renal injury, similar to CFU-ECs as described by
Patschan et al. (39). However, no ECFC delivered by intravascular injection were detectable in
postischemic kidneys, using confocal microscopy. While our search for cell homing was based on tracking
of labeled cells using confocal microscopy, it is clearly reasonable to suggest that a small number of ECFC
in kidney may not have been observed. Nevertheless, ECFCs were found primarily in lung and spleen. This
appears similar to the dynamics of intravascular transplanted mesenchymal stem cells from various origins
(53), which are thought to mediate their effects primarily via the production and release of soluble
vasoactive/or anti-inflammatory compounds. To further evaluate the endocrine nature of ECFC activity, we
also demonstrated that human ECFC-CM has protective activity against I/R injury (Fig. 4). These results
are also consistent with recent studies from Burger et al. (14), who also demonstrated that human ECFC did
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not home to the kidneys of SCID mice following I/R, but did protect against AKI measured at either 24 or
72 h post-I/R. These investigators also demonstrated ECFC-mediated protection was characterized by
significant attenuation of necrosis and apoptosis and a reduction in macrophage infiltration. Moreover, the
attenuation of apoptosis by ECFC extended to both the tubular compartment as wells as the vascular
compartment (14).
In viewing our results with respect to the hypothesis that endothelial dysfunction plays a primary role in the
genesis of AKI (5, 35), it is noteworthy that the effects of rat PMVEC and human ECFC-CM on renal I/R
appear to influence early alterations in renal hemodynamic function before the manifestation of significant
renal tubular damage. Given that the renal medulla is hypoxic relative to the cortex and receives a smaller
percentage of RBF, impaired perfusion in this region could exacerbate hypoxia and contribute toward
cellular injury in this susceptible region (12). The early impairment of renal MBF can be observed within a
few hours of reperfusion and is thought to correspond to the severity of the resulting injury (43).
Reductions in MBF are exacerbated by අ-NAME and ameliorated by the free radical scavenger N-acetyl
cysteine (18). In addition, Regner et al. (44) demonstrated that the reduction in MBF in the first 2 h
postischemia was abrogated by the 20-HETE analog 5,14, 20-HEDGE, which also mediated significant
protection against tissue damage at 24 h. In addition, other agents such as volatile anesthetics (27),
hydrogen sulfide, atrial natriuretic peptide, or the induction of heme-oxygenase-1 have all been shown to
attenuate the immediate loss of MBF following I/R injury (43). Taken together, these observations indicate
that the preservation of MBF represents an important mechanism by which either PMVEC or ECFC-CM
protects against I/R-induced AKI.
The protective effects on MBF may be a function of modulating the renal inflammatory response.
Inflammatory cell infiltration is a prominent early feature in the outer medullary vasa recta capillaries
following injury characterized by the progressive influx of leukocytes, lymphocytes, dendritic cells, and
macrophages into the interstitium (1, 22, 26, 28, 34, 66). It has been hypothesized that endothelial
activation promoting cell infiltration contributes to the severity of injury either by sustaining reductions in
perfusion and/or by promoting the liberation of cytokines which drive inflammation and injury (33).
In the current studies, we demonstrated that human ECFC-CM may influence early alterations in renal
hemodynamics in part by influencing the expression of ICAM-1, which is known be enhanced on the
surface of endothelial cells following I/R (11, 35, 70). Moreover, strategies using either antibodies or null
mutant mice designed to inhibit the contribution of ICAM-1 or other adhesion molecule activity have been
shown to reduce inflammation and the severity of AKI (23, 24, 26, 41, 48, 49).
While a variety of cells are known to invade the postischemic kidney, there is growing evidence the T cells
play a critical role in the development of AKI (19, 21, 32, 65, 67). It is interesting that ECFC-CM
influences the activation and differentiation of T cells in the postischemic kidney, as evidenced by the
reduced number of cells expressing the cytokine IL-17, including Th-17 cells (CD4+/IL17+). Recent
studies from our own laboratory have shown that Th17 cells represent the most prominent T-helper
population induced by renal I/R in rats (32). Moreover, Th17 infiltration is enhanced in vitamin D-deficient
rats, which exacerbates AKI (20), while Th17 cell infiltration is reduced by the administration of adipose-
derived stromal cells which attenuate AKI (25). A potential role for Th17 cells in the pathogenesis of AKI
is supported by studies in which mice lacking the IL-17A gene were protected against the development of
AKI induced by cisplatin (17, 32). It is possible that IL-17 produced from T cells may directly impact renal
hemodynamics in the setting of AKI, representing an additional mechanism by which PMVEC and
hECFC-CM convey vascular protection following ischemic injury. The suggestion that IL-17 may
contribute to vascular oxidant stress derives from studies indicating that reactive oxygen species generation
induced by ANG II is ablated in mice lacking the IL-17A gene. In addition, Nguyen et al. (38)
demonstrated that IL-17 activates RhoA-Rho-kinase, leading to endothelial dysfunction and hypertension
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in mice. We suggest that inhibition of adhesion molecule activity by ECFC-CM represents a potential
mechanism by which postischemic Th17 cell infiltration was attenuated; however, our results cannot
exclude the possibility that ECFC-CM may have a direct effect on lymphocyte activation.
The lack of homing and the similar effect of conditioned media suggest that factors released by ECFC may
preserve renal vascular function in the setting of AKI, in part, by targeting endothelial-leukocyte
interactions. It is plausible to suggest that factors derived from ECFC could be utilized clinically in high-
risk patients to mitigate the development of AKI. At the present time, the biochemical nature of the
factor(s) that mediate this protection is not clear. However, recent studies demonstrated that ECFC-derived
exosomes contain a high level of miR-486-5p and that inhibition of miR-486-5p attenuated the protective
effects of exosomes in hypoxia-challenged endothelial cells in vitro (59).
In summary, our results confirm previous studies that soluble factors produced by ECFC protect against the
development of AKI, and extend these results by indicating that protection is mediated in part by
preventing early loss in renal medullary perfusion. ECFC also reduce the expression of adhesion molecules
and attenuate the degree of inflammation, in particular, the infiltration of Th17 cells. The identification and
exploitation of these soluble factors will be of considerable interest in the future to determine whether the
effects of ECFC are mediated directly at the renal endothelium and/or influence inflammatory cells
activated in response to injury.
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Fig. 1.
Rat pulmonary microvascular endothelial cells (PMVEC) protect against renal ischemia-reperfusion (I/R) injury and
accelerate functional and structural recovery. A: serum creatinine (sCre) values for 7 days following I/R or sham surgery (n
= 3) in rats treated with vehicle (n = 7), pulmonary artery endothelial cells (PAEC; n = 6), or PMVEC (n = 8). B:
representative photomicrographs of periodic acid-Schiff (PAS)-stained kidney sections following 7 days of recovery from
renal I/R. Dilated tubules are prominent in vehicle and PAEC-treated rats (black arrows), with some evidence of cell
sloughing. Magnification is shown. C: results from a 2-day time course study comparing renal function in vehicle (n = 6)-
treated vs. PMVEC-treated rats (n = 6) following I/R injury. D: corresponding photomicrographs of PAS-stained kidney
sections following 2 days of recovery from renal I/R, indicating a greater degree of necrotic tubules (black arrows) in
vehicle-treated rats. E: injury score corresponding to 2-day postischemic rats. Data are means ± SE. * and # indicate P <
0.05 in PMVEC-treated rats compared with PAEC- and vehicle-treated rats, respectively by Student’s t-test.
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Fig. 2.
Open in a separate window
Rat PMVEC preserve medullary blood flow in the early postischemic period. Total renal blood (A) and medullary blood
flow (B) were monitored for 30 min before ischemia and up to 120 min postreperfusion as labeled. Data are averaged in
10-min time bins normalized to the baseline values for each rat, and data are means ± SE *P < 0.05 in vehicle- relative to
PMVEC-treated rats by ANOVA with repeated measures.
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Fig. 3.
Open in a separate window
Rat PMVEC do not home to the kidney following transplantation. Shown are representative confocal images of freshly
suspended PMVEC labeled with cell tracker red in vitro and imaged before transplantation (A). There were no labeled
cellular structures in the kidney at either 2 h (B) or 2 days (C) posttransplantation. D: fluorescently labeled cells in spleen
with a similar size and fluorescent intensity of preinfused PMVEC (white arrows). Similarly, labeled structures were
readily apparent in lung (not shown). Magnification is shown in A.
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Fig. 4.
Human endothelial colony-forming cells-conditioned medium (ECFC-CM) protects against renal I/R injury. A: serum
creatinine for 2 days following I/R or sham surgery (n = 3) in vehicle (n = 7)- and ECFC-CM-treated rats (n = 7). B:
representative photomicrographs of PAS-stained kidney sections following 2 days of recovery from renal I/R. Significant
necrotic debris and tubular damage are present in vehicle-treated rat kidney 2 days postsurgery (black arrows).
Magnification is shown. Tissue injury score is shown in C. D: KIM-1 mRNA expression in sham, vehicle-, or ECFC-CM-
treated rats. Data are means ± SE. n.d., Not detectable. *P < 0.05 in ECFC-CM-treated relative to vehicle-treated rats by
Student’s t-test.
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Fig. 5.
Open in a separate window
Human ECFC-CM preserves medullary blood flow in the early postischemic period. Total renal blood flow (A) and
medullary blood flow (B) were monitored for 30 min before ischemia and up to 120 min postreperfusion as labeled. Data
are averaged in 10-min time bins normalized to the baseline values for each rat and data are means ± SE. *P < 0.05 in
vehicle- relative to ECFC-CM-treated rats by ANOVA with repeated measures.
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Fig. 6.
Human ECFC-CM reduces adhesion molecular expression following recovery from I/R injury. Rats subjected to sham
surgery or renal I/R and recovery for 5 h. Rats were treated with vehicle or ECFC-CM as labeled. A: mRNA expression
levels for ICAM-1 derived from total RNA of whole kidney using real-time PCR. B and C: representative images of
kidney ICAM-1 immunofluorescence in sham, vehicle-, and ECFC-CM-treated rats. C: quantitative analysis of % total
area of ICAM-1 immunofluorescent-stained structures. Immunofluorescence data in C are % of total area compared with
the mean value of sham-operated control rats. *P < 0.05 sham vs. I/R+vehicle by Student’s t-test. #P < 0.05 in
I/R+vehicle- vs. I/R+ECFC-CM-treated rats.
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Fig. 7.
Open in a separate window
Human ECFC-CM reduces infiltration of inflammatory cells in kidneys following I/R. Kidney resident monocytes were
isolated from kidneys harvested 2 days postsurgery/treatment. A: gating strategy for FACS analysis. Lymphocytes were
gated based on forward and side scatter plot. Total number of infiltrating monocytes (B), total number of CD4+ T cells (C),
CD8+ T cells (D), total IL-17+ T cells (E), CD4+IL-17+ T cells (F), and IFN-γ+ cells (G) were quantified using
fluorescence-activated cell sorting. Data are expressed as total number of each cell type per gram of tissue and are means ±
SE. *P < 0.05 sham vs. I/R+vehicle by Student’s t-test. ϕP < 0.05 sham vs. I/R+ECFC-CM. #P < 0.05 I/R+vehicle vs.
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I/R+ ECFC-CM.
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